Table 2.
Predicted ADMET profile of hesperidin and Grazoprevir.
| Descriptor | Hesperidin | Grazoprevir |
|---|---|---|
| Molecular weight (g/mol) | 610.56 | 766.90 |
| Number of rotatable bonds | 7 | 9 |
| Number of H-bond donors | 8 | 3 |
| Number of H-bond acceptors | 15 | 12 |
| Log P | −0.72 | 4.142 |
| Gastrointestinal absorption | Low | Low |
| BBB permeability | No | No |
| Substrate of P-gp | Yes | Yes |
| CYP1A2 inhibitor | No | No |
| CYP2C19 inhibitor | No | No |
| CYP2C9 inhibitor | No | No |
| CYP2D6 inhibitor | No | No |
| CYP3A4 inhibitor | No | No |
| Bioavailability score | 0.17 | 0.17 |
| Log CLtot (mL/min/kg) | 0.211 | – |
| MRTD (mg/day) | 424 | 355 |
| Hepatotoxicity | No | No |
| Ames toxicity | No | No |
| hERG channel inhibition | Yes | Yes |